Indocyanine green may be highly sensitive in the identification of ovarian cancer metastases, though with low specificity.
|Articles|January 1, 2002
Oncology NEWS International
- Oncology NEWS International Vol 11 No 1
- Volume 11
- Issue 1
Two NIH Institutes Will Fund New Synchrotron Beamlines
BETHESDA, Maryland-Two National Institutes of Health (NIH) units will jointly fund the design and construction of three new synchrotron beamlines as a way to increase x-ray crystallography studies of proteins.
Advertisement
BETHESDA, MarylandTwo National Institutes of Health (NIH) units will jointly fund the design and construction of three new synchrotron beamlines as a way to increase x-ray crystallography studies of proteins.
The National Cancer Institute and the National Institute of General Medical Sciences expect the $23 million project to be fully operational in about 3 years. The three beamlines will be added to the new Advanced Proton Source at Argonne National Laboratory in Illinois.
Articles in this issue
over 24 years ago
ODAC Sends Mixed Message on New Gliadel Wafer Indicationalmost 25 years ago
ONCC Certification Test Results Are Announcedalmost 25 years ago
Rituximab Ups Survival in Aggressive and Indolent NHLalmost 25 years ago
Topotecan Used in Aggressive Front-Line Therapy for SCLCalmost 25 years ago
Depsipeptide Shows Activity in T-Cell Lymphomaalmost 25 years ago
FDG-PET Useful in Newly Diagnosed and Recurrent NSCLCalmost 25 years ago
Adjuvant Anastrozole Superior to Tamoxifen in Huge ATAC Breast Cancer Trialalmost 25 years ago
ODAC Backs Adding HER-2 DNA Test to Herceptin Package Insertalmost 25 years ago
FDA and VA Plan Joint AIDS Studyalmost 25 years ago
Breast Conservation Increases With On-Site Radiation UnitAdvertisement
Related to this article
The therapeutic cancer vaccine OSE2101 combined with either docetaxel or nivolumab met the primary end point of 1-year overall survival in the Combi-TED trial.
In a phase 1 trial, CD19/CD20/CD22 CAR T cells produced complete responses in 83% of patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
Nikolai Strusberg, MD, explained the clinical hypothyroidism endpoint and how thyroid dose should guide proton vs photon choice in breast cancer.
Leah Katz, MD, MPH, discusses IDEA, TARGIT-B, NeoORB, and other breast radiation data from ASTRO 2026, and why patient selection is the unifying theme.
Frederick Howard, MD, explored the evolving intersection of artificial intelligence (AI), computational pathology, and precision breast oncology.
“Vitamin C is a powerful epigenetic drug, which is not generally realized,” said Peter A. Jones, PhD, DSc (hon).
Findings from the AZUR-1 trial support the FDA approval of dostarlimab for patients with stage II/III locally advanced rectal cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Dostarlimab in Previously Untreated Locally Advanced Rectal Cancer
2
Is Vitamin C an Epigenetic Interception Strategy in Pre-Leukemic Disease?
3
AI Foundation Models & Molecular Biomarkers in Breast Cancer
4
Ris-Rez Produces Anti-Tumor Activity in Extensive-Stage SCLC
5